- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.04. | DIAGONAL BIO AB: Diagonal Bio announces change of news plattform | 1 | Cision News | ||
| 28.03. | DIAGONAL BIO AB: Diagonal Bio publishes Year-End Report for 2024 | 1 | Cision News | ||
| 21.03. | DIAGONAL BIO AB: Diagonal Bio granted patent in Japan | 1 | Cision News | ||
| 19.03. | Nomination Committee change in Diagonal Bio AB (publ.) | 1 | Cision News | ||
| 19.03. | DIAGONAL BIO AB: Trading in Diagonal Bio's shares and warrants of series TO 2 on NGM Nordic SME begins today | 1 | Cision News | ||
| 18.03. | NGM MARKET NOTICE: #25-27 Warrants issued by Diagonal Bio AB approved for listing at NGM | 2 | Cision News | ||
| 14.03. | NGM MARKET NOTICE: #25-23 Diagonal Bio AB approved for listing at NGM | 1 | Cision News | ||
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 13.03. | DIAGONAL BIO AB: Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify® | 1 | Cision News | ||
| 04.03. | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 203 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03. | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 183 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
| 03.03. | DIAGONAL BIO AB: Diagonal Bio applies for change of marketplace to NGM Nordic SME | 1 | Cision News | ||
| 19.02. | Diagonal Bio AB's announces last day of trading in BTU and first day of trading in warrants of series TO 2 | 2 | Cision News | ||
| 18.02. | Diagonal Bio AB resolves on a directed issue of units to all external underwriters | 4 | Cision News | ||
| 12.02. | DIAGONAL BIO AB: Diagonal Bio's CEO Karin Wehlin increases ownership | 1 | Cision News | ||
| 07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 329 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 05.02. | DIAGONAL BIO AB: Stall Goop conducts pilot test of LAMPlify® | 1 | Cision News | ||
| 29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 110 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
| 23.01. | The subscription period of Diagonal Bio AB's rights issue of units commences today | 1 | Cision News | ||
| 22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 195 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| 17.01. | DIAGONAL BIO AB: Nomination Committee change in Diagonal Bio (publ.) | 2 | Cision News |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock | ||
| CENTOGENE | 0,149 | +49,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,880 | +0,24 % | Atai Beckley: Big Deal | Fast genau vier Jahre nach dem Börsenstart am 18. Juni 2021 gibt es signifikante Veränderungen bei Atai Life Science: So schließt sich das auf die Behandlung psychischer Erkrankungen spezialisierte... ► Artikel lesen | |
| BIOMERIEUX | 119,80 | +0,50 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| CYCLACEL | 0,290 | -100,00 % | Cyclacel Pharmaceuticals, Inc.: Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement | KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company that develops innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 22,800 | +1,79 % | Dividendenbekanntmachungen (04.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,742 EUR BARCLAYS PLC GB0031348658 0,055 GBP EUR BRISTOL-MYERS SQUIBB COMPANY US1101221083 0... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,925 | -5,13 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| ABIONYX PHARMA | 1,164 | +0,34 % | ABIONYX Pharma Announces Approval of All Resolutions Put to the Vote at Its Combined General Meeting | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen | |
| ANAPTYSBIO | 20,000 | +4,17 % | AnaptysBio, Inc.: Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA | Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month? blinded treatment periodFavorable safety and tolerability, particularly... ► Artikel lesen | |
| MEIRAGTX | 5,600 | +1,82 % | MeiraGTx erhält britische Genehmigungen für Hologen-Transaktion | ||
| AKESO | 9,850 | -2,48 % | Akeso, Inc.: Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025 | HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16... ► Artikel lesen | |
| MAAT PHARMA | 4,910 | +1,66 % | MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies(MET) dedicated to enhancing... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,064 | -0,62 % | Isofol Medical AB: Isofol completes first cohort in ongoing clinical study with arfolitixorin | GOTHENBURG, Sweden, June 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the first cohort in the ongoing phase Ib/II clinical study with... ► Artikel lesen |
DIAGONAL BIO AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.